Want to see ELOX full AI Analyst Report?
Top Page
Eloxx Pharmaceuticals
(NASDAQ:ELOX)
Select Model
Select Model
Rating:43Neutral
Price Target:
$13.00
▼(-8.39% Downside)
Action:Reiterated
Date:10/22/26
The score is primarily held down by weak financial performance—persistent losses, ongoing cash burn, and negative equity—despite improved loss/cash-burn trends and lower debt. Technical indicators also point to a weak price trend (below key moving averages with negative MACD). Valuation contributes only modestly because the negative P/E reflects unprofitable operations and there is no dividend support.
Positive Factors
Loss and cash-burn reduction
The substantial reduction in net losses and operating cash burn indicates progress in controlling the cost base and prioritizing development spending. Although Eloxx remains unprofitable, a lower burn rate can extend financial runway and make future funding needs more manageable.
Negative Factors
No durable commercial revenue
The absence of consistent commercial revenue means Eloxx does not yet have an operating business that independently funds research, trials, or corporate costs. Its financial outlook therefore remains tied to clinical progress and access to external capital rather than recurring product demand.
Read all positive and negative factors
Positive Factors
Negative Factors
Loss and cash-burn reduction
The substantial reduction in net losses and operating cash burn indicates progress in controlling the cost base and prioritizing development spending. Although Eloxx remains unprofitable, a lower burn rate can extend financial runway and make future funding needs more manageable.
Read all positive factors
Eloxx Pharmaceuticals (ELOX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$51.67M
Dividend YieldN/A
Average Volume (3M)24.50K
Price to Earnings (P/E)―
Beta (1Y)-2653.88
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees10
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.52
Shares Outstanding4,036,459
10 Day Avg. Volume25,674
30 Day Avg. Volume24,502
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)-1.04
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.62
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.95
Forecast
1Y Price Target
$38.25Price Target Upside169.56% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.1
Revenue Forecast (FY)N/A
Eloxx Pharmaceuticals Business Overview & Revenue Model
Company Description
Eloxx Pharmaceuticals is a clinical-stage biopharmaceutical firm that specializes in developing therapeutic solutions through ribosome modulation. Its primary objective is to address rare and ultra-rare genetic diseases that arise from premature s...
How the Company Makes Money
Eloxx Pharmaceuticals does not have a broadly disclosed, recurring commercial product revenue base; null. As a clinical-stage biotechnology company, its funding and any revenue it reports typically come from a combination of (i) collaboration or l...
Eloxx Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
22
Negative
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 6.36M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 6.36M | 0.00 | -695.00K | -960.00K |
| EBITDA | -8.18M | -4.95M | -1.83M | -15.09M | -33.50M | -64.51M |
| Net Income | -8.26M | -6.00M | -3.14M | -17.05M | -36.06M | -66.73M |
Balance Sheet | ||||||
| Total Assets | 63.39M | 5.27M | 2.98M | 1.71M | 21.12M | 45.14M |
| Cash, Cash Equivalents and Short-Term Investments | 61.96M | 4.79M | 111.00K | 1.13M | 19.47M | 42.57M |
| Total Debt | 0.00 | 1.00M | 6.52M | 3.97M | 13.38M | 13.46M |
| Total Liabilities | 16.97M | 17.18M | 27.31M | 24.31M | 31.78M | 22.75M |
| Stockholders Equity | 46.42M | -11.91M | -24.34M | -22.60M | -10.66M | 22.38M |
Cash Flow | ||||||
| Free Cash Flow | -10.24M | 0.00 | -4.71M | -14.34M | -31.91M | -35.09M |
| Operating Cash Flow | -10.24M | -6.33M | -4.71M | -14.34M | -31.84M | -35.00M |
| Investing Cash Flow | 0.00 | 1.00K | 38.00K | 309.00K | -66.00K | 2.06M |
| Financing Cash Flow | 67.42M | 11.00M | 3.44M | -4.08M | 8.81M | 50.79M |
Eloxx Pharmaceuticals Risk Analysis
Eloxx Pharmaceuticals disclosed 46 risk factors in its most recent earnings report. Eloxx Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Eloxx Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $3.87M | -0.18 | -166.67% | ― | ― | 88.77% | |
43 Neutral | $51.67M | -8.42 | -42.52% | ― | ― | ― | |
43 Neutral | $435.60K | >-0.01 | -42.42% | ― | ― | 97.97% | |
42 Neutral | $6.24M | -0.04 | 952.76% | ― | -21.49% | 84.62% |
* Healthcare Sector Average
ELOX
Eloxx Pharmaceuticals
12.80
11.70
1063.64%
AIM
AIM ImmunoTech
0.16
-2.46
-94.04%
BDRX
Biodexa Pharmaceuticals
0.42
-36.81
-98.86%
DRMA
Dermata Therapeutics
0.78
-3.29
-80.81%
VRAX
Virax Biolabs Group Ltd. Class A
1.22
-13.38
-91.64%
Eloxx Pharmaceuticals Corporate Events
Business Operations and StrategyExecutive/Board Changes
Eloxx Pharmaceuticals Advances Leadership and Phase 2 Kidney Trial
Positive
Oct 22, 2026
On October 19, 2026, Eloxx Pharmaceuticals expanded its Board and appointed Geno J. Germano as an independent director, adding deep pharmaceutical leadership and public-company board expertise to its governance while granting him standard indemnit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.